SCHEMBL7971868

SCHEMBL7971868

Cc1ccc(C(N)=NO)cc1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.66
GFER P55789 1/20 0.66
KMT2A Q03164 1/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
PRSS1 P07477 1/20 0.57
PRSS2 P07478 1/20 0.57
PRSS3 P35030 1/20 0.57
RECQL P46063 1/20 0.50
MAPT P10636 3/20 0.48
GAA P10253 3/20 0.48
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 3/20 0.42
MITF O75030 1/20 0.42
POLB P06746 1/20 0.42
KDM1A O60341 4/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16367706 1.00 LMNA (0.66) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL17737724 1.00 LMNA (0.66) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL19859062 0.83 MAPT (0.57) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL14741800 0.83 MAPT (0.57) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL31748721 0.83 RECQL (0.61) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL30935544 0.83 MAPT (0.57) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL19798095 0.83 LMNA (0.49) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL2569248 0.82 LMNA (0.47) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL17737809 0.82 LMNA (0.51) LMNAGFERKMT2AL3MBTL1PRSS1
SCHEMBL17730412 0.82 LMNA (0.51) LMNAGFERKMT2AL3MBTL1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215505-B1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE Bayer Pharma AG (DE) 2019-07-24 EP disclosed
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-06 US disclosed
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-23 US disclosed
EP-3215505-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2017-09-13 EP disclosed
WO-2016071216-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-12 WO disclosed
WO-2001054507-A1 METHODS FOR KILLING NEMATODES AND NEMATODE EGGS USING OXADIAZOLE AND OXAIMIDAZOLE COMPOUNDS AKKADIX CORPORATION (US) 2001-08-02 WO disclosed
WO-2001002375-A1 PROCESS FOR SYNTHESIZING OXADIAZOLES CHEMRX ADVANCED TECHNOLOGIES, INC. (US) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use HAMP, SERPINC1, PRSS8 LMNA 2585/4885GFER 3201/4885KMT2A 3881/4885
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE HAMP, SERPINC1, PRSS8 LMNA 2585/4885GFER 3201/4885KMT2A 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.